Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

VVOS vs AVR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AVR Captures Overall Composite Edge (42.0 HOLD vs 36.4 SELL), While VVOS Leads 3–2 on Growth & Valuation Pillars

AVR Overall Winner 6-Pillar Tally: VVOS 3 – 2 AVR (1 Tie) Matrix Metrics: VVOS 2 – 6 AVR

As of Nov 20, 2026, Anteris Technologies Global Corp. (AVR) captures the overall head-to-head institutional edge over Vivos Therapeutics, Inc. (VVOS) on higher Unified Composite conviction (42.0/100 HOLD vs. 36.4/100 SELL) after splitting the core matrix 6–2 (led by Profitability & Quality, Options & Positioning), while VVOS wins 3–2 across the 6-pillar growth and valuation breakdown. VVOS trades at $0.05 (N/M Forward P/E, -107.9% operating margin) versus AVR at $4.99 (N/M Forward P/E, -4880.4% operating margin).

  • Growth vs. Quality Trade-Off: AVR earns the overall head-to-head edge with a stronger Unified Composite Score (42.0/100 HOLD vs. VVOS 36.4/100 SELL) and 1.49β · 78% Vol risk profile, whereas VVOS leads top-line expansion (+34.9% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: VVOS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 18.9); meanwhile AVR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VVOS vs AVR
VVOS NASDAQ
Vivos Therapeutics, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.05
-5.1% 1D
Market Cap $1.9M
TTM Revenue $21M
Forward P/E N/M
Beta / 30D Vol 1.70β · 111% Vol
Unified Composite Score
36.4 / 100 SELL
Tech 25.0 Fund 35.0 Flow 50.0 Mom 30.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -29.8%), weak momentum, RSI 19
RSI-14: 18.9 · SMA20: $0.10 · SMA50: $0.13
AVR NASDAQ Head-to-Head Winner
Anteris Technologies Global Corp. Common Stock
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$4.99
-1.96% 1D
Market Cap $496.2M
TTM Revenue $2.3M
Forward P/E N/M
Beta / 30D Vol 1.49β · 78% Vol
Unified Composite Score
42.0 / 100 HOLD
Tech 32.0 Fund 52.0 Flow 57.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -16.0%), weak momentum, RSI 34
RSI-14: 34.4 · SMA20: $5.75 · SMA50: $6.63

6-Pillar Scorecard Institutional Category Breakdown (VVOS 3 – 2 AVR)

Columns: Metric · VVOS · AVR
1. Valuation Multiples VVOS
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 0.1x 120.1x
2. Growth & Scale VVOS
Revenue Growth (YoY) +34.9% +21.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $21M $2.3M
Market Cap $1.9M $496.2M
3. Profitability & Quality AVR
Gross Margin 61.9% 75.8%
Operating Margin -107.9% -4880.4%
Net Profit Margin -121.8% 0.0%
Return on Equity (ROE) -8585.3% -93.3%
4. Balance Sheet & Cash Flow VVOS
Cash Generation (TTM) -$21M EBITDA -$94M
Cash Flow Margin -99.3% EBITDA Mgn N/A
Net Cash / Leverage -8585.3% ROE $216M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AVR
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile N/A (N/A) 151.1% (69th %ile)
Put/Call OI Skew N/A 4.63x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VVOS (2) vs AVR (6)
Institutional Metric VVOS AVR Criterion Row Edge
Market Capitalization
Scale
$1.9M $496.2M Larger Scale AVR
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+34.9% +21.0% Higher Growth VVOS
Operating Margin (TTM)
Profitability
-107.9% -4880.4% Higher Margin VVOS
Net Profit Margin
Profitability
-121.8% 0.0% Higher Margin AVR
Return on Equity (ROE)
Capital Efficiency
-8585.3% -93.3% Higher ROE AVR
52-Week Range Position
Momentum
0% ($0–$3) 22% ($3–$11) Stronger Trend AVR
Beta / 30D Volatility
Risk Regime
1.70β · 111% Vol 1.49β · 78% Vol Lower Realized Risk AVR
Unified Institutional Score
Composite Signal
36.4 / 100 (SELL) 42.0 / 100 (HOLD) Higher Composite AVR
Trailing 12M Revenue (USD)
Operating Scale
$21M $2.3M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
61.9% 75.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.1x EV/Rev N/M PEG · 120.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$21M EBITDA (-8585.3% ROE) -$94M ($216M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AVR +42.42 pp
VVOS: -59.25% · AVR: -16.83%
3M Horizon AVR +37.19 pp
VVOS: -80.49% · AVR: -43.3%
6M Horizon AVR +43.02 pp
VVOS: -91.15% · AVR: -48.13%
1Y Horizon AVR +144.47 pp
VVOS: -97.71% · AVR: +46.76%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period VVOS Revenue AVR Revenue VVOS Op. Margin AVR Op. Margin Margin Leader
FY2019 $10M N/A -92.8% N/A VVOS
FY2020 $10M N/A -92.1% N/A VVOS
FY2021 $20M N/A -120.7% N/A VVOS
FY2022 $20M N/A -156.2% N/A VVOS
FY2023 $10M N/A -125.3% N/A VVOS
FY2024 $20M $0M -74.3% -2899.4% VVOS
FY2025 $20M $0M -114.1% -4908.2% VVOS

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VVOS BREAKDOWN
113d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact VVOS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AVR BREAKDOWN
105d in phase · OBV DISTRIBUTION
Current IV 151.1%
IV Percentile 69th %ile
Put/Call OI Skew 4.63x (Put-Skewed)
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact AVR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VVOS Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $1.9M market capitalization and -107.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
AVR Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $496.2M market capitalization and -4880.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ VVOS vs AVR Key Questions & Quantitative Answers

As of Nov 20, 2026, Anteris Technologies Global Corp. (AVR) captures the overall head-to-head institutional edge over Vivos Therapeutics, Inc. (VVOS) on higher Unified Composite conviction (42.0/100 HOLD vs. 36.4/100 SELL) after splitting the core matrix 6–2 (led by Profitability & Quality, Options & Positioning), while VVOS wins 3–2 across the 6-pillar growth and valuation breakdown. VVOS trades at $0.05 (N/M Forward P/E, -107.9% operating margin) versus AVR at $4.99 (N/M Forward P/E, -4880.4% operating margin). Growth vs. Quality Trade-Off: AVR earns the overall head-to-head edge with a stronger Unified Composite Score (42.0/100 HOLD vs. VVOS 36.4/100 SELL) and 1.49β · 78% Vol risk profile, whereas VVOS leads top-line expansion (+34.9% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: VVOS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 18.9); meanwhile AVR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

VVOS leads the Growth & Scale pillar: VVOS posts +34.9% YoY revenue growth and +0.0% YoY earnings growth on $21M TTM revenue (61.9% gross margin, -107.9% operating margin), compared with AVR at +21.0% YoY revenue growth and +0.0% YoY earnings growth on $2.3M TTM revenue (75.8% gross margin, -4880.4% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), VVOS cumulative revenue shifted +100.0% while AVR shifted N/A. In operating R&D and SG&A reinvestment, VVOS deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AVR.

VVOS screens cheaper on headline valuation multiples. VVOS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.1x EV/Revenue (-99.3% EBITDA margin), whereas AVR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 120.1x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VVOS (-8585.3% ROE) versus AVR (-93.3% ROE) capital efficiency.

In options market volatility and institutional positioning, VVOS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.70β · 111% Vol realized risk). By comparison, AVR carries 151.1% implied volatility (69th %ile, Elevated (60th–80th %ile)), a 4.63x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.49β · 78% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.